GCT3013-05

• Relapsed or refractory disease and previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since lymphoma diagnosis
• One of the confirmed histologies below with CD20-positivity:
  • a. DLBCL, NOS, including de novo or histologically transformed from FL
  • b. “”Double-hit”” or “”triple-hit”” DLBCL (technically classified in WHO 2016 as HGBCL, with MYC and BCL2 and/or BCL6 translocations), including de novo or histologically transformed from FL
  • c. FL Grade 3B
• ECOG PS score of 0-2
• Failed previous HDT-ASCT or not eligible for HDT-ASCT at screening
• Patients must have detectable disease by PET scan and measurable by CT scan or MRI
• Acceptable renal and liver function
• Life expectancy >2 months on SOC treatment

• Primary CNS tumor or known CNS involvement
• Any prior therapy with a bispecific antibody targeting CD3 and CD20
• Major surgery within 4 weeks prior to randomization
• Chemotherapy and other non-investigational antineoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to randomization
• Any investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to randomization
• ASCT within 100 days of randomization
• Treatment with CAR-T therapy within 100 days prior to randomization
• Seizure disorder requiring anti-epileptic therapy
• Clinically significant cardiac disease

View more trial information